Uropathogenic Escherichia coli infection: Potential importance of epigenetics

Epigenomics

Volumn 4, Issue 2, 2012, Pages 229-235

  Tolg, Cornelia ^a   Bägli, Darius J ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

bladder; CDKN2A; DNA methylation; DNA methyltransferase; Helicobacter pylori; infection recurrence; Schistosoma mansoni; urinary tract infection; uroepithelium; uropathogenic Escherichia coli

Indexed keywords

ANTIBIOTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; BLADDER EPITHELIUM; DEFENSE MECHANISM; DNA METHYLATION; EPIGENETICS; ESCHERICHIA COLI INFECTION; HOST CELL; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL; RECURRENCE RISK; TUMOR SUPPRESSOR GENE; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; UROPATHOGENIC ESCHERICHIA COLI INFECTION;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL CELLS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; HUMANS; PREDICTIVE VALUE OF TESTS; URINARY TRACT INFECTIONS; UROPATHOGENIC ESCHERICHIA COLI;

ESCHERICHIA COLI; HELICOBACTER PYLORI; MAMMALIA; SCHISTOSOMA MANSONI;

EID: 84859193507     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.5     Document Type: Article

References (40)

1. Freedman AL. Urologic Diseases in America. Litwin MS, Saigal CS (Eds). US department of health and human services, public health service, national institutes of health, national institute of diabetes and digestive and kidney diseases. Washington, DC, USA (2007).
2. Mangiarotti P, Pizzini C, Fanos V. Antibiotic prophylaxis in children with relapsing urinary tract infections: review. J. Chemother. 12(2), 115-123 (2000).
3. Jantunen ME, Saxen H, Salo E, Siitonen A. Recurrent urinary tract infections in infancy: relapses or reinfections? J. Infect. Dis. 185(3), 375-379 (2002).
4. Mattoo TK. Vesicoureteral reflux and reflux nephropathy. Adv. Chronic Kidney Dis. 18(5), 348-354 (2011).
5. Avlan D, Gundogdu G, Taskinlar H, Delibas A, Nayci A. Relationships among vesicoureteric reflux, urinary tract infection and renal injury in children with non-neurogenic lower urinary tract dysfunction. J. Pediatr. Urol. 7(6), 612-615 (2011).
6. Mulvey MA, Lopez-Boado YS, Wilson CL et al. Induction and evasion of host defenses by Type 1-piliated uropathogenic Escherichia coli. Science 282(5393), 1494-1497 (1998).
7. Zhou G, Mo WJ, Sebbel P et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J. Cell Sci. 114(Pt 22), 4095-4103 (2001).
8. Mak RH, Kuo HJ. Pathogenesis of urinary tract infection: an update. Curr. Opin. Pediatr. 18(2), 148-152 (2006).
9. Ragnarsdottir B, Lutay N, Gronberg-Hernandez J, Koves B, Svanborg C. Genetics of innate immunity and UTI susceptibility. Nat. Rev. Urol. 8(8), 449-468 (2011). Provides an overview of the role of innate immunity in urinary tract infection.
10. Weichhart T, Haidinger M, Horl WH, Saemann MD. Current concepts of molecular defence mechanisms operative during urinary tract infection. Eur. J. Clin. Invest. 38(Suppl. 2), 29-38 (2008).
11. Berry RE, Klumpp DJ, Schaeffer AJ. Urothelial cultures support intracellular bacterial community formation by uropathogenic Escherichia coli. Infect. Immun. 77(7), 2762-2772 (2009).
12. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol. 7(8), 430-441 (2010).
13. Hawn TR, Scholes D, Wang H et al. Genetic variation of the human urinary tract innate immune response and asymptomatic bacteriuria in women. PLoS ONE 4(12), e8300 (2009).
14. Zaffanello M, Malerba G, Cataldi L et al. Genetic risk for recurrent urinary tract infections in humans: a systematic review. J. Biomed. Biotechnol. 2010, 321082 (2010).
15. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 6(8), e1001042 (2010). Discusses the link between inflammatory response and urinary tract infection recurrence.
16. Shin K, Lee J, Guo N et al. Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472(7341), 110-114 (2011). Discusses signaling pathways regulating uroepithelial stem cell proliferation and differentiation.
17. Tasian G, Cunha G, Baskin L. Smooth muscle differentiation and patterning in the urinary bladder. Differentiation 80(2-3), 106-117 (2010).
18. Gutierrez MI, Siraj AK, Khaled H, Koon N, El-Rifai W, Bhatia K. CpG island methylation in Schistosoma-and non-Schistosoma-associated bladder cancer. Mod. Pathol. 17(10), 1268-1274 (2004).
19. Stein RA. Epigenetics - the link between infectious diseases and cancer. JAMA 305(14), 1484-1485 (2011). Provides an overview of infection-induced epigenetic alterations.
20. Niwa T, Tsukamoto T, Toyoda T et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 70(4), 1430-1440 (2010).
21. Niwa T, Ushijima T. Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. Adv. Genet. 71, 41-56 (2010).
22. Wolff EM, Chihara Y, Pan F et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 70(20), 8169-8178 (2010).
23. Kovalenko VM, Bagnyukova TV, Sergienko OV et al. Epigenetic changes in the rat livers induced by pyrazinamide treatment. Toxicol. Appl. Pharmacol. 225(3), 293-299 (2007).
24. Tolg C, Sabha N, Cortese R et al. Uropathogenic E. coli infection provokes epigenetic downregulation of CDKN2A (p16INK4A) in uroepithelial cells. Lab. Invest. 91(6), 825-836 (2011). Provides proof-of-concept that infection of uroepithelial cells with uropathogenic Escherichia coli induces hypermethylation of host cell DNA.
25. Tatemichi M, Hata H, Tazawa H, Nakadate T. Lipopolysaccharide induces aberrant hypermethylation of Hic-1 in mouse embryonic fibroblasts lacking p53 gene. Anticancer Res. 28(4B), 2101-2108 (2008).
26. Yin X, Hou T, Liu Y et al. Association of Toll-like receptor 4 gene polymorphism and expression with urinary tract infection types in adults. PLoS ONE 5(12), e14223 (2010).
27. Ragnarsdottir B, Jonsson K, Urbano A et al. Toll-like receptor 4 promoter polymorphisms: common TLR4 variants may protect against severe urinary tract infection. PLoS ONE 5(5), e10734 (2010).
28. Takahashi K, Sugi Y, Hosono A, Kaminogawa S. Epigenetic regulation of TLR4 gene expression in intestinal epithelial cells for the maintenance of intestinal homeostasis. J. Immunol. 183(10), 6522-6529 (2009).
29. Suhs KA, Marthaler BR, Welch RA, Hopkins WJ. Lack of association between the Tlr4 (Lpsd/Lpsd) genotype and increased susceptibility to Escherichia coli bladder infections in female C3H/HeJ mice. MBio 2(3), e00094-e00011 (2011).
30. Schulz WA. Uropathogenic bacteria leave a mark. Lab. Invest. 91(6), 816-818 (2011). Discusses article by Tolg et al. [24].
31. Verdoodt B, Sommerer F, Palisaar RJ et al. Inverse association of p16(INK4a) and p14(ARF) methylation of the CDKN2a locus in different Gleason scores of prostate cancer. Prostate Cancer Prostatic. Dis. 14(4), 295-301 (2011).
32. Sterlacci W, Tzankov A, Veits L et al. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J. Thorac. Oncol. 6(10), 1649-1657 (2011).
33. Miyamoto K, Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn. J. Clin. Oncol. 35(6), 293-301 (2005).
34. Phe V, Cussenot O, Roupret M. Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int. 104(7), 896-901 (2009).
35. Friedrich MG, Weisenberger DJ, Cheng JC et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10(22), 7457-7465 (2004).
36. Costa VL, Henrique R, Danielsen SA et al. TCF21 and PCDH17 methylation: an innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics doi:10.4161/epi.6.9.16376 (2011) (Epub ahead of print).
37. Haruki S, Imoto I, Kozaki K et al. Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis 31(6), 1027-1036 (2010).
38. Reinert T, Modin C, Castano FM et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res. 17(17), 5582-5592 (2011).
39. Hansen KD, Timp W, Bravo HC et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43(8), 768-775 (2011).
40. ImageJ Software. http://rsb.info.nih.gov/ij